t5.jpg

 
 



  BLOG::

  Adam Welsh

p4.jpg

 
Subscribe to our blog to track news and events, learn about upcoming events, hear insightful perspectives and learn more about our services and solutions
 

2010.05.01 | 2010.04.01

Thursday, May 13, 2010

FDA's Bad Ad Program Seeks Surveillance Help from the Health Professional Community
The US Food and Drug Administration (FDA, www.fda.gov) has launched a program to engage health professionals in helping to detect and report misleading prescription drug advertising.  The program is being administered by the Division of Drug Marketing, Advertising and Communication (DDMAC, link) in the Center for Drug Evaluation & Research (CDER).  Historically, DDMAC focused on approving marketing materials submitted by drug companies for approval, response to consumer complaints and field activities at large public venues but did not have a robust program to address the proliferation of targeted direct to consumer advertising.  With issues and the potential for abuse growing, DDMAC has embarked on a program to directly entreat the health professional community to voluntarily serve as watchdogs for DDMAC and the FDA ("FDA: ‘Bad Ad Program’ to Help Health Care Providers Detect, Report Misleading Drug Ads").  The hope is that by leveraging the knowledge and significant "eyeballs" of our nation's health professional community that reporting of misleading, inaccurate or unsafe pharmaceutical advertising will increase and improve the FDA's ability to regulate product marketing.  While not clearly stated, it is implied that these new reporting avenues will tie into other FDA post-market surveillance activities if a direct enforcement activity does not occur.  It will be interesting to see how the FDA's reform of its MedWatch program to MedWatch Plus and the continued development of an enterprise-wide adverse event reporting system (FAERS) and the plan to contract services to monitor the internet to identify the potential illegal sale and marketing of FDA regulated products.  These activities are part of a significant push by the FDA to address consumer and product safety and as these activities grow and strengthen we should see more robust protection of the public health and attendant improvements in safety and quality of health outcomes.
12:58 pm edt          Comments

Thursday, April 22, 2010

Thanks for visiting our site
Thanks very much for visiting our site.  We will be blogging a few times a week about things of interest in our industry or within our company so please stay tuned! 
4:41 pm edt          Comments

Wednesday, April 21, 2010

10:40 am edt          Comments

Link to web log's RSS file

       
 

i3.jpg
 




240.479.9117  


Powered by:Register.com